MOUNTAIN VIEW, California, May 29, 2014 /PRNewswire/ -- The heightened private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008-2010, witnessed a decline post-2010. However, the fall in deals was not uniform among the constituent sectors, with the pharmaceutical, biotechnology and healthcare equipment sectors experiencing a much sharper decline in investor interest than the healthcare technology and provider segments. Investors started to bet on providers based with the conviction they can provide quicker and safer returns than the pharmaceutical and biotechnology space, which is ridden with regulatory challenges and patent expiries.
Image: http://www.freedigitalphotos.net
To read the original article: Frost & Sullivan: A Rise in IPOs Revive Investments for the Global Pharma and Biotech Industry - MarketWatch
